Total Payments
$188,608
2024 Payments
$16,146
Companies
21
Transactions
187
Medicare Patients
551
Medicare Billing
$144,771
Payment Breakdown by Category
Consulting$124,845 (66.2%)
Research$39,994 (21.2%)
Travel$12,796 (6.8%)
Other$9,099 (4.8%)
Food & Beverage$1,850 (1.0%)
Gifts$25.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $124,845 | 49 | 66.2% |
| Unspecified | $39,994 | 81 | 21.2% |
| Travel and Lodging | $12,796 | 24 | 6.8% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $3,965 | 1 | 2.1% |
| Honoraria | $2,763 | 6 | 1.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,371 | 2 | 1.3% |
| Food and Beverage | $1,850 | 23 | 1.0% |
| Gift | $25.00 | 1 | 0.0% |
Payments by Type
General
$148,614
106 transactions
Research
$39,994
81 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $65,618 | 38 | $0 (2024) |
| Novartis Pharma AG | $27,120 | 19 | $0 (2024) |
| Amgen Inc. | $13,008 | 15 | $0 (2019) |
| Astellas Pharma Global Development | $12,228 | 56 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $11,405 | 10 | $0 (2024) |
| Agios Pharmaceuticals, Inc. | $10,326 | 13 | $0 (2020) |
| Celgene Corporation | $9,901 | 6 | $0 (2021) |
| ABBVIE INC. | $8,213 | 4 | $0 (2022) |
| PFIZER INC. | $5,000 | 1 | $0 (2017) |
| Epizyme, Inc. | $4,038 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,146 | 18 | Novartis Pharma AG ($5,672) |
| 2023 | $5,826 | 4 | NOVARTIS PHARMACEUTICALS CORPORATION ($3,223) |
| 2022 | $29,231 | 18 | Novartis Pharma AG ($12,933) |
| 2021 | $38,277 | 37 | Novartis Pharmaceuticals Corporation ($22,434) |
| 2020 | $29,521 | 37 | Novartis Pharmaceuticals Corporation ($12,857) |
| 2019 | $31,944 | 35 | Amgen Inc. ($10,202) |
| 2018 | $15,833 | 21 | Agios Pharmaceuticals, Inc. ($5,826) |
| 2017 | $21,829 | 17 | Novartis Pharmaceuticals Corporation ($10,736) |
All Payment Transactions
187 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/15/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $187.63 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 12/08/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $453.74 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 11/22/2024 | Epizyme, Inc. | Tazverik (Drug) | Consulting Fee | Cash or cash equivalent | $637.50 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Epizyme, Inc. | Tazverik (Drug) | Consulting Fee | Cash or cash equivalent | $637.50 | General |
| Category: Oncology | ||||||
| 11/20/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $2,257.50 | General |
| 10/11/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $453.74 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 08/01/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $187.63 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 07/19/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ICLUSIG (Drug) | Consulting Fee | Cash or cash equivalent | $3,806.25 | General |
| Category: ONCOLOGY | ||||||
| 06/15/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $431.05 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 06/07/2024 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $2,362.50 | General |
| 06/01/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | — | Cash or cash equivalent | $209.71 | Research |
| Study: CABL001J12301 • Category: Oncology | ||||||
| 05/31/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $453.74 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 05/30/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $563.47 | General |
| 04/24/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $187.63 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 04/15/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $985.68 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 03/01/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $178.25 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 02/06/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | In-kind items and services | $187.63 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 01/08/2024 | Novartis Pharma AG | SCEMBLIX (Drug) | — | Cash or cash equivalent | $1,965.00 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 12/07/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Consulting Fee | Cash or cash equivalent | $3,037.50 | General |
| 12/07/2023 | NOVARTIS PHARMACEUTICALS CORPORATION | — | Food and Beverage | In-kind items and services | $185.89 | General |
| 11/09/2023 | Ipsen Biopharmaceuticals, Inc | Tazverik (Drug) | Consulting Fee | Cash or cash equivalent | $637.50 | General |
| Category: Oncology | ||||||
| 06/12/2023 | Novartis Pharma AG | SCEMBLIX (Drug) | — | Cash or cash equivalent | $1,965.00 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 12/22/2022 | Novartis Pharma AG | SCEMBLIX (Drug) | — | Cash or cash equivalent | $1,965.00 | Research |
| Study: CABL001J12301 • Category: ONCOLOGY | ||||||
| 12/09/2022 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug) | Food and Beverage | In-kind items and services | $69.62 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 09/27/2022 | JAZZ PHARMACEUTICALS INC. | VYXEOS (Drug) | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CABL001J12301 | Novartis Pharma AG | $14,187 | 15 |
| CPKC412E2301 | Novartis Pharma AG | $5,240 | 1 |
| A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia AML with FLT3 Mutation | Astellas Pharma Global Development | $4,154 | 9 |
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | Astellas Pharma Global Development | $3,849 | 23 |
| A Phase 3 Open-label Multicenter Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. | Astellas Pharma Global Development | $3,341 | 18 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $2,683 | 1 |
| DSP-7888 | Sumitomo Dainippon Pharma Co., Ltd. | $1,800 | 1 |
| A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO CHARACTERIZE THE EFFICACY AND SAFETY OF A RANGE OF DOSES | Takeda Pharmaceuticals U.S.A., Inc. | $1,500 | 2 |
| OPTIC- Phase 2 CML Efficacy-Safety | Takeda Pharmaceuticals U.S.A., Inc. | $843.75 | 1 |
| A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation. | Astellas Pharma Global Development | $687.97 | 4 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $608.00 | 1 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $395.00 | 1 |
| A PHASE III MULTI CENTER OPEN LABEL RANDOMIZED STUDY OF IMATINIB VERSUS NILOTINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE PH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE CML CP | Novartis Pharmaceuticals Corporation | $300.00 | 1 |
| CABL001J12301 | Novartis Pharmaceuticals Corporation | $209.71 | 1 |
| Phase 3, Randomized, Multicenter, Open-Label Trial in Asi | Astellas Pharma Global Development | $130.00 | 1 |
| A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation | Astellas Pharma Global Development | $65.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 159 | 474 | $211,384 | $46,139 |
| 2022 | 6 | 123 | 315 | $139,004 | $27,997 |
| 2021 | 5 | 111 | 246 | $111,309 | $24,153 |
| 2020 | 5 | 158 | 520 | $216,768 | $46,482 |
Total Patients
551
Total Services
1,555
Medicare Billing
$144,771
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 43 | 302 | $124,816 | $29,958 | 24.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 22 | 51 | $30,939 | $5,921 | 19.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 28 | 33 | $27,518 | $4,780 | 17.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 23 | 34 | $14,363 | $2,570 | 17.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 31 | 40 | $9,752 | $1,984 | 20.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 14 | $3,996 | $925.54 | 23.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 26 | 176 | $70,688 | $14,963 | 21.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 31 | 50 | $34,336 | $5,976 | 17.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 16 | $13,092 | $2,679 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 21 | 28 | $10,666 | $2,009 | 18.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 17 | 25 | $5,805 | $1,415 | 24.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Facility | 2022 | 13 | 20 | $4,417 | $954.30 | 21.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 43 | 109 | $64,766 | $13,291 | 20.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 68 | $25,982 | $6,050 | 23.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 15 | 20 | $8,182 | $1,733 | 21.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2021 | 20 | 28 | $5,980 | $1,581 | 26.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 19 | 21 | $6,399 | $1,499 | 23.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 41 | 309 | $115,941 | $27,823 | 24.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 39 | 107 | $58,789 | $9,725 | 16.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 21 | 22 | $16,006 | $3,740 | 23.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 34 | 54 | $16,122 | $3,725 | 23.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 23 | 28 | $9,910 | $1,470 | 14.8% |
About Richard Larson
Richard Larson is a Hematology & Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1114089661.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Richard Larson has received a total of $188,608 in payments from pharmaceutical and medical device companies, with $16,146 received in 2024. These payments were reported across 187 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($124,845).
As a Medicare-enrolled provider, Larson has provided services to 551 Medicare beneficiaries, totaling 1,555 services with total Medicare billing of $144,771. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Chicago, IL
- Active Since 12/14/2006
- Last Updated 10/24/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1114089661
Products in Payments
- SCEMBLIX (Drug) $24,772
- TIBSOVO (Drug) $14,337
- RYDAPT (Drug) $13,986
- XOSPATA (Drug) $11,344
- ICLUSIG (Drug) $11,312
- ABL002 (Drug) $6,269
- VENCLEXTA (Drug) $5,400
- PKC412E_RYDAPT_HEMATOLOGY (Drug) $5,240
- IBRANCE (Drug) $5,000
- TASIGNA (Drug) $4,824
- ONUREG (Drug) $3,951
- VYXEOS (Drug) $3,767
- CALQUENCE (Drug) $3,438
- Blincyto (Biological) $3,057
- Venclexta (Drug) $2,813
- IMLYGIC (Biological) $2,806
- TAZVERIK (Drug) $2,763
- Nplate (Biological) $2,744
- Idhifa (Drug) $2,100
- Tazverik (Drug) $1,913
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chicago
Michael Bishop
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Young Kwang Chae, Md, Mph, Mba, MD, MPH, MBA
Hematology & Oncology — Payments: $682,642
Hematology & Oncology $682,642
Irfan Mirza, Md, MD
Hematology & Oncology — Payments: $644,273
Hematology & Oncology $644,273
Everett Vokes
Hematology & Oncology — Payments: $449,910
Hematology & Oncology $449,910
Peter Riedell
Hematology & Oncology — Payments: $374,919
Hematology & Oncology $374,919
Rita Nanda
Hematology & Oncology — Payments: $374,678
Hematology & Oncology $374,678